Yes — psilocybin therapy is legal in Canada when accessed through Health Canada's Special Access Program (SAP). The legal framework has three layers: federal (CDSA Schedule III), Health Canada (SAP framework via the January 5, 2022 amendment), and provincial (medical regulator standards). Psilocybin has no Health Canada approved indication, so the standard prescribing pathway is closed; the SAP pathway is the only legal therapeutic route. Recreational possession is illegal under CDSA Schedule III with criminal penalties. Storefront vendors selling psilocybin-containing products in legally ambiguous arrangements operate outside Health Canada authorization; some have been subject to enforcement actions. This article walks through the legality framework honestly, compares Canadian psilocybin's legal status to MDMA (also SAP-only) and ketamine (off-label legal access plus Spravato approval), and clarifies what is and isn't legal at each access level.
Key takeaways
- Yes — psilocybin therapy is legal in Canada via the Special Access Program (SAP). The January 5, 2022 SAP amendment created the durable practitioner-initiated pathway.
- Federal: CDSA Schedule III — controlled substance, prescription-required where authorized. No Health Canada approved indication.
- Recreational possession is illegal under CDSA Schedule III; criminal penalties apply.
- Provincial: medical regulators have not generally issued specific psilocybin policies. Off-label psilocybin prescribing outside SAP would be highly unusual and likely subject to college review.
- Compared to ketamine: ketamine is also CDSA Schedule I but has a Health Canada anaesthetic indication, making off-label psychiatric use legal standard practice. Psilocybin has no equivalent approved indication, so SAP is the only legal therapeutic pathway.
- Compared to MDMA: same SAP framework. MDMA SAP applications more commonly target PTSD; psilocybin SAP applications more commonly target end-of-life distress and TRD.
- Storefront vendors selling psilocybin products in legally ambiguous arrangements operate outside Health Canada authorization and are not part of any clinical or legal therapeutic framework.
The federal layer — CDSA Schedule III
Psilocybin is controlled under Schedule III of the Controlled Drugs and Substances Act (CDSA). The practical implications:
- Prescription required where authorized. Psilocybin can only be obtained legally through Health Canada-authorized pathways — currently SAP-only since psilocybin has no approved Canadian therapeutic indication.
- Recreational possession is illegal. Possession outside legal authorization carries criminal penalties under the CDSA.
- Manufacturing and distribution are tightly controlled. Pharmaceutical-grade synthetic psilocybin is supplied through Health Canada-licensed Canadian producers (Filament Health, Optimi Health, Psyence Group) only for SAP-authorized use or research.
- Authorized therapeutic use is legal. Schedule III status does not prohibit medical use; it controls who may prescribe and dispense and under what conditions.
The federal framework is summarized at Canada.ca — Psilocybin and psilocin.
The Health Canada layer — SAP
The Special Access Program is the only legal therapeutic pathway. Three regulatory milestones:
August 4, 2020 — Section 56(1) exemptions
Health Canada granted Section 56(1) exemptions to four terminally ill Canadians for psilocybin-assisted therapy for end-of-life distress — the first legal therapeutic psilocybin access in Canada in decades. Result of TheraPsil-led advocacy.
January 5, 2022 — SAP amendment
Health Canada amended the Food and Drug Regulations to allow practitioner-initiated SAP requests for psilocybin (and MDMA) for serious or life-threatening conditions where conventional treatments have failed. The amendment repealed 2013 restrictions that had previously excluded restricted drugs from SAP.
Ongoing — case-specific authorization
Each SAP authorization is for one patient, one course of treatment. There is no commercial or class authorization for general clinical use. The patient cannot apply directly; the prescribing physician or nurse practitioner submits the request.
For the regulatory deep dive, see Health Canada SAP for Psilocybin. For the patient-friendly access pathway, see How to Access Psilocybin Therapy in Canada.
The provincial layer — medical regulator standards
Provincial medical regulators — CPSA Alberta, CPSO Ontario, CPSBC British Columbia, CPSS Saskatchewan, CMQ Quebec, CPSM Manitoba, the Atlantic colleges — have not generally issued specific psilocybin policies. The general framework:
- Off-label psilocybin prescribing outside SAP would be highly unusual and likely subject to college review. Without an approved Canadian indication, SAP is the only legal therapeutic pathway.
- CPSA Alberta has issued psychedelic-assisted therapy guidance applicable to clinic operations, including ATMA CENA's corporate clinics in Edmonton and Calgary.
- Quebec specifically: Bill 21 (loi 21, 2009) reserves psychotherapy as a regulated act, with implications for who can deliver the psychotherapy component of psilocybin-assisted therapy in Quebec. See Psilocybin Therapy in Quebec.
- Other provinces: physicians practicing within provincial regulator standards, federal CDSA, and SAP authorization can deliver SAP-pathway psilocybin therapy. Specific clinic-accreditation requirements applicable to ketamine (e.g., CPSA NSHF, CPSO OHPIP, CPSBC NHMSFAP for IV ketamine) generally do not apply to oral psilocybin in the same way; the regulatory architecture differs.
Comparison to ketamine — different regulatory architectures
A common patient question is "if ketamine is legal, why isn't psilocybin?" The two have different Canadian regulatory architectures:
| Psilocybin | Ketamine | |
|---|---|---|
| CDSA schedule | Schedule III | Schedule I |
| Health Canada approved indication | None | Anaesthetic (since decades) |
| Off-label psychiatric use legal? | No — no approved indication closes the off-label pathway | Yes — off-label is legal standard practice on the back of the anaesthetic indication |
| SAP required for psychiatric use? | Yes (only legal pathway) | No |
| Approved psychiatric product? | None | Spravato (esketamine, May 2020 for TRD) |
The honest framing: ketamine's anaesthetic approval gives it an off-label legal pathway that psilocybin does not have. Psilocybin's lack of any approved Canadian indication is what closes the off-label door and makes SAP the sole legal therapeutic route.
If Health Canada were to approve a psilocybin product (e.g., Compass Pathways' COMP360 for TRD if their Phase 3 program succeeds), the regulatory architecture would change — opening standard prescribing pathways and provincial formulary review. See Health Canada SAP for Psilocybin for the future-pathway framing.
For ketamine's legal framework specifically, see Is Ketamine Therapy Legal in Canada?.
Comparison to MDMA — same SAP framework
MDMA-assisted therapy in Canada operates under the same January 5, 2022 SAP framework as psilocybin. Both substances were added to SAP eligibility in the amendment.
Differences in practice:
- MDMA SAP applications more commonly target PTSD (the indication with strongest published RCT evidence — Mitchell 2021 MAPP1 and Mitchell 2023 MAPP2 Phase 3 trials).
- Psilocybin SAP applications more commonly target end-of-life distress, TRD, AUD, and demoralization.
- MDMA SAP approvals have been substantially fewer than psilocybin per industry reporting (~41 MDMA vs ~176 psilocybin as of February 2024).
- MDMA's regulatory future: the FDA declined to approve MDMA-AT in August 2024 following a Lykos Therapeutics application; Canadian access remains SAP-only.
For MDMA-PTSD comparison context, see Ketamine Therapy for PTSD (which discusses MDMA-AT as a comparison framing).
Storefront vendors — legally ambiguous
Some Canadian retailers (storefronts and online) sell psilocybin-containing products outside the SAP framework. The legal reality:
- Health Canada does not authorize these sales for therapeutic or recreational use. Products sold by these vendors are not part of any approved clinical or legal therapeutic pathway.
- Some have been subject to enforcement actions by Health Canada and provincial law enforcement.
- Legal status is unsettled: civil disobedience claims, free-trade arguments, and public-interest exemption claims have been raised in defense of these vendors but have not generally been validated by courts.
- Consumer caution: products purchased from these vendors are not pharmaceutical-grade, do not have verified potency, are obtained outside SAP authorization, and are subject to the criminal-possession provisions of CDSA Schedule III.
ATMA CENA does not endorse, recommend, or facilitate purchases from non-licensed psilocybin vendors. The legal SAP-pathway alternative — accessed through a willing prescribing physician — is the only Canadian framework ATMA CENA operates within.
For ATMA CENA's editorial position on related questions like microdosing, see Microdosing Psilocybin.
Recreational psilocybin — illegal
Recreational possession of psilocybin or psilocybin-containing mushrooms outside SAP authorization is illegal under CDSA Schedule III. Penalties:
- Possession: up to 3 years' imprisonment for indictable offence; up to 6 months for summary conviction.
- Trafficking, production, possession for the purpose of trafficking: more severe penalties depending on circumstances.
The practical reality of enforcement varies by jurisdiction and circumstances, but the legal status is clear.
Penalties summary
| Activity | Legal status |
|---|---|
| SAP-pathway therapeutic psilocybin with prescriber authorization | Legal |
| Off-label psilocybin prescribing without SAP (where no approved indication exists) | Highly unusual; likely subject to college review |
| Recreational possession | Illegal under CDSA Schedule III |
| Trafficking, production | Illegal under CDSA Schedule III with serious penalties |
| Storefront sales without Health Canada authorization | Operating outside legal therapeutic framework; subject to enforcement |
| Cultivation for personal use | Illegal under CDSA Schedule III |
Does the legal pathway require Quebec or Alberta residency?
No. SAP authorization is a federal Health Canada framework available to patients in all provinces. Differences in public funding apply: Quebec has the only established public-funding precedent (Farzin/Stephan billed RAMQ December 2022), and Alberta Blue Cross PAT (March 2024) covers ketamine-assisted therapy with psilocybin coverage framed as future potential.
For the Quebec-specific deep dive, see Psilocybin Therapy in Quebec. For cost coverage, see Psilocybin-Assisted Therapy Cost in Canada.
Frequently asked questions
Is psilocybin therapy legal in Canada? Yes — when accessed through Health Canada's Special Access Program with prescriber authorization. The legal pathway has been operational since the January 5, 2022 SAP amendment.
Is recreational psilocybin legal? No. Recreational possession is illegal under CDSA Schedule III with criminal penalties.
Why isn't psilocybin treated like ketamine if both are controlled substances? Ketamine has a Health Canada anaesthetic approval that opens off-label legal psychiatric prescribing. Psilocybin has no approved Canadian indication, so SAP is the only legal therapeutic pathway.
What about storefront vendors selling psilocybin products? Operating outside Health Canada authorization. Legal status is unsettled; some have been subject to enforcement. Not part of any clinical or legal therapeutic framework.
Can my doctor just prescribe psilocybin off-label like ketamine? No. Without an approved Canadian indication, off-label prescribing outside SAP would be highly unusual and likely subject to college review. SAP is the legal framework for therapeutic access.
Will psilocybin become approved in Canada? Possibly, depending on Phase 3 trial outcomes (Compass Pathways most prominently). Health Canada NOC approval would substantially expand access.
Is microdosing legal? No. Self-directed microdosing using illicit-market psilocybin operates under recreational possession, which is illegal. Microdosing is not part of the SAP pathway. See Microdosing Psilocybin.
What about Quebec or Alberta — different rules? Federal SAP framework applies in all provinces. Quebec has the only established public-funding precedent (RAMQ); Alberta has provincial regulator guidance on psychedelic-assisted therapy (CPSA) and Alberta Blue Cross private coverage for ketamine. See Psilocybin Therapy in Quebec.
Can I travel to a country where psilocybin is legal and use it there? Some countries (Netherlands, Jamaica) have legally ambiguous frameworks for psilocybin retreats. Doing so is a personal-autonomy choice; ATMA CENA does not endorse or facilitate. Patients pursuing this pathway do so outside the Canadian legal and clinical framework. Importing psilocybin into Canada is illegal without proper authorization.
What about Oregon or Colorado psilocybin services? US state-level psilocybin frameworks (Oregon Measure 109, Colorado Proposition 122) operate under state law within the US. They are not legal pathways for Canadian residents and cannot be used as a substitute for SAP authorization in Canada.
Are there decriminalization efforts in Canada? Various advocacy groups have proposed decriminalization, but no Canadian province or the federal government has enacted decriminalization for psilocybin specifically.
What if I get caught with psilocybin? Possession is a criminal offence under CDSA Schedule III. Penalties include imprisonment up to 3 years for indictable offence; up to 6 months for summary conviction. Practical enforcement varies; legal consequences can be material.
Sources
- Government of Canada — Psilocybin and psilocin: https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.html
- Government of Canada — Controlled Drugs and Substances Act: https://laws-lois.justice.gc.ca/eng/acts/C-38.8/
- Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
- Health Canada — Section 56(1) class exemptions: https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/policy-regulations/policy-documents/subsection-56-1-class-exemption-practitioners-agents-pharmacists-persons-charge-hospital-hospital-employees-licensed-dealers-conduct-activities-psilocybin-mdma-relation-special-access-program-authorization.html
- Canada Gazette Part II — January 5, 2022 amendment: https://gazette.gc.ca/rp-pr/p2/2022/2022-01-05/html/sor-dors271-eng.html
- TheraPsil: https://therapsil.ca/
- PsyCan / Psychedelics Canada: https://psychedelicscanada.org/
- CPSA — psychedelic-assisted therapy guidance: https://cpsa.ca/
Related articles
- Psilocybin Therapy in Canada
- How to Access Psilocybin Therapy in Canada (SAP)
- Health Canada SAP for Psilocybin
- Microdosing Psilocybin
- Psilocybin Therapy in Quebec
- Is Ketamine Therapy Legal in Canada?
- Psilocybin Therapy FAQs
Last updated: 2026-05-06